Exparel
Total Payments
$12.8M
Transactions
44,033
Doctors
24,623
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 13,019 | 9,217 |
| 2023 | $2.7M | 10,705 | 7,725 |
| 2022 | $3.5M | 10,724 | 6,697 |
| 2021 | $3.7M | 9,585 | 6,019 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5.9M | 1,587 | 46.2% |
| Honoraria | $2.3M | 779 | 18.1% |
| Food and Beverage | $1.3M | 36,859 | 9.9% |
| Current or prospective ownership or investment interest | $964,415 | 27 | 7.5% |
| Travel and Lodging | $922,064 | 4,647 | 7.2% |
| Grant | $794,181 | 27 | 6.2% |
| Unspecified | $292,921 | 37 | 2.3% |
| Space rental or facility fees (teaching hospital only) | $211,384 | 49 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,724 | 7 | 0.6% |
| Education | $31,757 | 12 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,135 | 2 | 0.0% |
Payments by Type
General
$12.5M
43,996 transactions
Research
$292,921
37 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery | Pacira Pharmaceuticals Incorporated | $242,319 | 0 |
| Analgesic Requirement for Post-Operative Pain Control in Elective 1-3 Level Transforaminal Lumbar Interbody Fusion: Comparison of Thoracolumbar Interfascial Plane Block with EXPAREL to Marcaine | Pacira Pharmaceuticals Incorporated | $30,602 | 0 |
| Preoperative (Pre-amputation) Cryoanalgesia to Improve Post-amputation Phantom Limb Pain, General physical and emotional disability, and Opioid Consumption: a randomized pilot trial | Pacira Pharmaceuticals Incorporated | $20,000 | 0 |
Top Doctors Receiving Payments for Exparel — Page 985
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MSN RN NPC | Critical Care Medicine | Lowell, MA | $4.80 | 2 |
| , M.D | Orthopaedic Surgery | Bronx, NY | $4.80 | 2 |
| , MPAS, PA-C | Surgical | Norfolk, VA | $4.80 | 2 |
| , D.O | Physical Medicine & Rehabilitation | Greenwich, CT | $4.80 | 2 |
| , MD | Sports Medicine | Cincinnati, OH | $4.80 | 2 |
| , C.R.N.A | Nurse Anesthetist, Certified Registered | Zachary, LA | $4.80 | 2 |
| , D.O | Internal Medicine | Worcester, MA | $4.80 | 2 |
| , MD, MBA | Physical Medicine & Rehabilitation | Pocatello, ID | $2.55 | 1 |
| , M.D | Anesthesiology | Grand Island, NE | $1.89 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Charlevoix, MI | $1.89 | 1 |
| , CRNA | Nurse Anesthetist, Certified Registered | Fargo, ND | $1.89 | 1 |
| , M.D | Interventional Pain Medicine | Summit, WI | $1.89 | 1 |
| , PA | Physician Assistant | Salt Lake City, UT | $1.89 | 1 |
| , PA-C | Specialist | Flagstaff, AZ | $1.89 | 1 |
| , M.D | Anesthesiology | Bismarck, ND | $1.89 | 1 |
| , DO | Sports Medicine | Rochester, NY | $1.89 | 1 |
| , MD | Diagnostic Radiology | Durham, NC | $1.89 | 1 |
| , PA-C | Surgical | Portland, ME | $1.89 | 1 |
| , D.O | Sports Medicine | Rochester, NY | $1.89 | 1 |
| , DO | Anesthesiology | Syracuse, NY | $1.30 | 1 |
| , CRNA | Specialist | Fremont, NE | $1.30 | 1 |
| , MD | Anesthesiology | Sunrise, FL | $1.30 | 1 |
| , FNP-C | Family | Virginia Beach, VA | $1.30 | 1 |
| , M.D | Adult Medicine | Springfield, MO | $1.30 | 1 |
Ad
Manufacturing Companies
- Pacira Pharmaceuticals Incorporated $12.8M
- Pacira Therapeutics, Inc. $1,166
Product Information
- Type Drug
- Total Payments $12.8M
- Total Doctors 24,623
- Transactions 44,033
About Exparel
Exparel is a drug associated with $12.8M in payments to 24,623 healthcare providers, recorded across 44,033 transactions in the CMS Open Payments database. The primary manufacturer is Pacira Pharmaceuticals Incorporated.
Payment data is available from 2021 to 2024. In 2024, $2.8M was paid across 13,019 transactions to 9,217 doctors.
The most common payment nature for Exparel is "Consulting Fee" ($5.9M, 46.2% of total).
Exparel is associated with 3 research studies, including "A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery" ($242,319).